The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-D-Ala-D-Ala Segment of the Peptidoglycan Pentapeptide Stem

James Chang,† Hongyu Zhou,‡ Maria Preobrazhenskaya,§ Peng Tao,‡ and Sung Joon Kim*,†

†Department of Chemistry and Biochemistry, Baylor University, Waco, Texas 76706, United States
‡Department of Chemistry, Center for Drug Discovery, Design, and Delivery (CD4), Center for Scientific Computation, Southern Methodist University, Dallas, Texas 75275, United States
§Gause Institute of New Antibiotics, Moscow, Russian Federation

ABSTRACT: Glycopeptide antibiotics inhibit cell wall biosynthesis in Gram-positive bacteria by targeting the peptidoglycan (PG) pentapeptide stem structure (i-Ala–d-iso-Gln–l-Lys–d-Ala–d-Ala). Structures of the glycopeptide complexed with a PG stem mimic have shown that the d-Ala–d-Ala segment is the primary drug binding site; however, biochemical evidence suggests that the glycopeptide–PG interaction involves more than d-Ala–d-Ala binding. Interactions of the glycopeptide with the non-d-Ala–d-Ala segment of the PG stem were investigated using solid-state nuclear magnetic resonance (NMR). LCTA-1421, a double [15N]enriched eremomycin derivative with a C-terminal [15N]amide and [13C]Asn amide, was complexed with whole cells of Staphylococcus aureus grown in a defined medium containing L-[3,13C]Ala and D-[1,13C]Ala in the presence of alanine racemase inhibitor alaphospin. [15N] and [13C] rotational-echo double-resonance (REDOR) NMR measurements determined the 13C–15N internuclear distances between the [15N]Asn amide of LCTA-1421 and the 13C atoms of the bound D-[1-13C]Ala–D-[1-13C]Ala to be 5.1 and 4.8 Å, respectively. These measurements also determined the distance from the C-terminal [15N]amide of LCTA-1421 to the L-[3-13C]Ala of PG to be 3.5 Å. The measured REDOR distance constraints position the C-terminus of the glycopeptide in the proximity of the L-Ala of the PG, suggesting that the C-terminus of the glycopeptide interacts near the l-Ala segment of the PG stem. In vivo REDOR measurements provided structural insight into how C-terminally modified glycopeptide antibiotics operate.

Vancomycin is a glycopeptide antibiotic exhibiting potent activities against almost all strains of Gram-positive cocci and bacilli. In 1956, Eli Lilly and Company discovered vancomycin in soil samples collected from Borneo; the antibiotic was being produced by the soil microbe Amycolatopsis orientalis. Since the discovery of vancomycin, researchers have identified ~50 different glycopeptide antibiotic-producing organisms with more than 100 different natural glycopeptides. All glycopeptides have a heptapeptide core (aglycon) structure formed by heavily cross-linked amino acids through a series of phenolic oxidative couplings. The glycopeptides are classified into four types on the basis of their chemical structure (Supplementary Figure S1). Vancomycin is a Type I glycopeptide with methylated leucine and asparagine at the first and third positions of the aglycon, respectively. In Type II glycopeptides, such as avoparcin, the first and third residues are replaced by aromatic amino acids. Type III and IV glycopeptides also have aromatic amino acids at the first and third positions, but they are cross-linked by a phenolic–ether linkage. Ristocetin is an example of a Type III glycopeptide, with its aglycon structure modified by six sugar adducts. Teicoplanin, a Type IV glycopeptide, has an aglycon core structure identical to that of Type III but differs by an acyl chain attached to the sugar moiety.

Glycopeptides inhibit peptidoglycan (PG) biosynthesis by binding to lipid II, a membrane-bound PG precursor. This behavior was discovered when vancomycin was added to cell extracts of Staphylococcus aureus inhibited the formation of the PG (Figure 1) and the incorporation of glycine into lipid II. When vancomycin is added to whole cells of bacteria, cytoplasmic precursors accumulate (Park’s nucleotide) and the cell wall becomes thinner. These results support the hypothesis that vancomycin inhibits transglycosylation by targeting lipid II. By binding to lipid II, vancomycin effectively sequesters the lipid transporter C55, the limiting factor in PG biosynthesis, which is present only in a small number of copies per bacterium. The lipid transporter is regenerated from lipid II only during the transglycosylation step of PG biosynthesis.
Binding of vancomycin to D-Ala-D-Ala was first identified when vancomycin failed to inhibit in vitro PG polymerization of UDP-MurNac-tetrapeptide purified from the membrane fractions of Gaffkya homari. Because the UDP-MurNac-tetrapeptide lacked the terminal D-Ala found on the PG-pentapeptide stem (Figure 1), it was inferred that vancomycin operates in part by binding to the terminal D-Ala-D-Ala segment of PG. When the addition of the D-Ala-D-Ala dipeptide antagonized vancomycin’s activities, this finding confirmed that the D-Ala-D-Ala segment of PG is the vancomycin binding site. The vancomycin dissociation constant for acyl-D-Ala-D-Ala, determined by capillary electrophoresis, is 4.3 μM.8

Figure 2 shows the X-ray crystal structure of vancomycin bound to diacetyl-L-Lys-D-Ala-D-Ala9 and the solution-state NMR structure of chloroeremomycin complexed with PG precursor analogue L-Ala-D-iso-Glu-L-Lys-D-Ala-D-Ala.10 Both vancomycin and chloroeremomycin share an identical heptapeptide core structure that forms the D-Ala-D-Ala binding site. Five hydrogen bonds stabilize the D-Ala-D-Ala segment as it is attached to the aglycon structure (Figure 2, bottom). (i) The first three H-bonds are located between the amide protons (NH2-NH4) and the carboxyl oxygen on the C-terminus of the D-Ala-D-Ala segment. (ii) A fourth bond is located between the carbonyl oxygen on the fourth residue of the aglycon (CO4) and an amide proton of the terminal D-Ala. (iii) A fifth bond is located between the amide proton of the seventh residue of the aglycon (NH7) and the carbonyl oxygen of the l-Lys. The hydrophobic interactions between the aromatic residues of the glycopeptide core structure and the methyl group of the alanines in the dipeptide are thought to further stabilize the drug-bound structure. In both X-ray crystal and solution-state NMR structures, the disaccharides of vancomycin and chloroeremomycin do not participate in D-Ala-D-Ala binding.

Structure and activity studies of glycopeptides and biochemical evidence suggest that in vivo glycopeptide–PG binding is far more complex than mere D-Ala-D-Ala dipeptide binding. Some of the evidence is listed here. (1) The strength of the glycopeptide’s binding affinity for D-Ala-D-Ala does not correlate with the drug’s activity. For example, the binding affinity between chloroeremomycin and diacetyl-L-Lys-D-Ala-D-Ala is approximately 23 times lower than that of vancomycin, but its activity is approximately 5–10 times
greater. (2) The chlorine atom on the second amino acid of vancomycin improves the activity. The dechlorinated vancomycin (monodechlorovancomycin) is only half as active as vancomycin. (3) The removal of sugars from vancomycin (deglycosylated vancomycin) does not affect D-Ala-D-Ala binding, but it reduces the activity by a factor of 5. The sugars on vancomycin have been attributed to the formation of a drug dimer, but in vivo glycopeptides are found as monomers,12−16 which suggests that the sugars enhance the activity by facilitating PG binding through sugar−PG interactions.15 (4) Methylated leucine, the first amino acid on vancomycin, is crucial for activity. The Edman degradation removal of leucine destroys the dipeptide binding affinity and its activity. (5) Asparagine, the third residue of vancomycin, does not participate in D-Ala-D-Ala binding but is required for its activity.17 Replacing asparagine with glutamine (lengthening the side chain by one carbon) or replacing it with an aspartate (introducing negative charge) reduces the activity by 2- and 10-fold, respectively. Substitution of asparagine with isoaspartate destroys the antimicrobial activity.2,11 (6) Alkylation of the drug sugar by a hydrophobic side chain improves the activity.18−21 (7) The carboxyl-terminal modifications of the glycopeptide improve the activity even though it is not involved in D-Ala-D-Ala binding.22

In this study, we investigate in vivo glycopeptide−PG binding interactions using solid-state NMR. Unlike solution-state NMR and X-ray diffraction structures based on the drug bound to PG-mimicking peptides, solid-state NMR allows direct investigation of the glycopeptide−PG complex in intact whole cells of S. aureus. To probe the glycopeptide−PG interactions, we have synthesized eremomycin derivative LCTA-1421 (Figure 3, top). LCTA-1421 is a bis[15N]amide-carboxyeremomycin with two 15N isotope-labeled probes: (1) a [15N]amide at the asparagine side chain of the aglycon structure positioned inside the D-Ala-D-Ala binding pocket and (2) a C-terminal [15N]amide at the seventh amino acid position. The first probe, [15N]amide asparagine of LCTA-1421, was used to characterize the structure of the LCTA-1421 aglycon.
bound to the d-Ala-d-Ala segment of the PG stem in whole cells. We anticipated that the in situ glycan structure of LCTA-1421 bound to the d-Ala-d-Ala segment of PG in the cell wall will be different from the solution-state NMR and X-ray diffraction structures based on the drug bound to a model peptide that suffers from the artifacts of drug dimerization and crystal lattice constraints, respectively. The in situ glycan structure of LCTA-1421 bound to PG was inferred from the intermolecular $^{13}$C−$^{15}$N distance measurements between the Asn [15N]amide of LCTA-1421 and the $^{13}$C atoms in d-[1-13C]Ala, d-[1-13C]Ala of the PG stem using rotational-echo double-resonance (REDOR) NMR.23,24

The second probe, the C-terminal [15N]amide of LCTA-1421, was used to determine whether interaction of the glycopeptide with the non-d-Ala-d-Ala segment of the PG stem structure by measuring the $^{13}$C−$^{15}$N distance between the C-terminal [15N]amide of LCTA-1421 and the $^{13}$C in L-[3-13C]Ala of the PG stem. LCTA-1421 exhibits improved antimicrobial activity versus that of the parent compound (Supplementary Table S2), which suggests that the interaction of the C-terminal [15N]amide of LCTA-1421 with the non-d-Ala-d-Ala segment of PG stem is important for enhancing antimicrobial activity. Thus, further understanding the interactions of the glycopeptide with the non-d-Ala-d-Ala segment of the PG stem is crucial for the future development of novel therapeutic agents, in particular against the vancomycin-resistant enterococci whose mechanism of vancomycin resistance is based on modification of the d-Ala-d-Ala segment of the PG stem to d-Ala-d-Lac.

### MATERIALS AND METHODS

**Synthesis of LCTA-1421 and LCTA-1110.** The synthesis of bis[15N]amide-carboxyremomycin (LCTA-1421) was described by Solov’eva et al.25 Briefly, eremomycin was treated with barium hydroxide at 37 °C for 4 h to yield carboxyremomycin.17 $^{[15N]}$Ammonium chloride was used to incorporate $^{15}$N-enriched labels at amino acid positions 3 and 7 of carboxyremomycin using PyBOP and HBPyU as condensing reagents.25 The MS-ESI-calculated mass for LCTA-1421 (C$_7$H$_{10}$N$_4$O$_2$N$_2$Cl, [M + H]$^+$) was 1557.57, and the found ([M + 2H]$^+$) mass was 779.80. The chemical shift of the $^{15}$N-amide at the C-terminus (amino acid position 7) was 110.22 ppm, and the $^{[15N]}$amide side chain of asparagine (amino acid position 3) was 113.28 ppm as determined by solution-state NMR. The synthesis of eremomycin p-fluorophenylpiperazinamide (LCTA-1110) has been described elsewhere,26 but briefly, LCTA-1110 was obtained by condensation of eremomycin with 4-fluorophenylpiperazine using PyBOP or HBPyU as a condensing reagent.

**Minimum Inhibitory Concentrations of Glycopeptide Antibiotics.** As recommended by the National Committee for Clinical Laboratory Standards, the microdilution method using Mueller-Hinton broth determined minimal inhibitory concentrations (MICs) for vancomycin, eremomycin, LCTA-1421, and LCTA-1110 against Staphylococcus epidermidis, Staphylococcus hemolyticus, vancomycin-intermediate-resistant S. aureus (VISA), vancomycin-susceptible Enterococcus faecium, vancomycin-susceptible Enterococcus faecalis, vancomycin-resistant E. faecium (VanA type), and vancomycin-resistant E. faecalis (VanA type).

**Growth of Whole Cells of S. aureus.** A starter culture of S. aureus (ATCC 6538P) was added (1% final volume) to a 1 L flask containing 250 mL of sterile S. aureus standard medium (SASM), which consists of l-[3-13C]Ala and d-[1-13C]Ala in the presence of the alanine racemase inhibitor alaphosphen (5 mg/L). The detailed protocol for preparing SASM has been described elsewhere.15,16,27 The cells were harvested at an optical density of 660 nm of 1.0, washed twice, and then resuspended in 10 mL of water containing 7.1 mg of LCTA-1421. After 10 min on ice, the LCTA-1412−bacterium complex was frozen using liquid N$_2$ and then lyophilized. The lyophilized sample weight was 250 mg.

**Solid-State NMR Spectrometer and REDOR NMR Parameters.** REDOR NMR experiments were performed on an 89 mm bore Oxford (Cambridge, England) superconducting solenoid at 4.7 T (200 MHz for $^1$H), using a four-frequency transmission line probe with a Chemagnetics/Varian ceramic stator. The samples were contained in a 7.5 mm outside diameter zirconia rotor spinning at 5 kHz at room temperature. Radiofrequency pulses for $^{13}$C and $^{15}$N were produced by 1 kW ENI (Andover, MA) LPI-10 power amplifiers. Radiofrequency pulses for $^1$H were produced by a 1 kW Kalmus Engineering Ltd. (Valencia, CA) power amplifier and the $^{19}$F pulses by a 1 kW Dressler Hochfrequenztechnik GmbH (Stolberg-Vicht, Germany) power amplifier. All four amplifiers were under active control. Radiofrequency pulse lengths for the $\pi$ pulse were 10 µs for $^{13}$C and $^{15}$N, and 25 µs for Proton−carbon and proton−nitrogen matched cross-polarization transfers were at 50 kHz for 2 ms. Proton dipolar decoupling during signal acquisition was 105 kHz. Standard XY-8 phase cycling28 was used for all refocusing and dephasing pulses.

The REDOR NMR method recouples heteronuclear dipolar interactions under magic-angle spinning (MAS)25,26 to determine heteronuclear dipolar couplings and hence inter-nuclear distances. REDOR NMR has been described elsewhere.15,16,27 Briefly, in the full-echo ($S_0$) spectrum, dipolar dephasing is refocussed over a single rotor period by MAS. In the $S$ spectrum, the spin part of the dipolar interaction prevented full refocussing via application of dephasing $\pi$ pulses, which reduced the peak intensity for dipolar coupled spin pairs. The difference in signal intensity ($\Delta S = S_0 − S$) for the observed spin ($^{13}$C or $^{15}$N) is directly related to the heteronuclear dipolar coupling from which the corresponding distance to the dephasing spin is determined. The normalized REDOR difference ($\Delta S/S_0$), based on the peak height measurements, is a direct measure of dipolar coupling, which was calculated using the modified Bessel function expressions given by Mueller et al.29 and de la Caillerie and Fretigny30 for an IS spin−$^{1/2}$ pair. The error bar for each REDOR dephasing was determined on the basis of the maximal noise peak intensity with respect to the dephased peak intensity.

**Molecular Dynamics Simulation of the PG-LCTA-1421 Complex.** Molecular dynamics simulation of LCTA-1421 bound to the PG pentapeptide stem structure was performed without water molecules to focus on the drug−target binding interactions. The initial model was generated on the basis of the NMR structure of chloroeremomycin complexed to the PG stem structure (L-Ala-d-iso-Gln-L-Lys-D-Ala-d-Ala) (PDB entry 1GAC). The CHARMM General Force Field (CGenFF)31 for the simulating system was generated using the online server ParamChem (https://cgenff.paramchem.org/). After a 20 ns molecular dynamics simulation, the following distance constraints were applied: (i) 3.5 Å between l-[3-13C]Ala and a [15N]amide at the C-terminus of LCTA-1421, (ii) 5.1 Å between d-[1-13C]Ala and the asparagine [15N]amide in LCTA-1421, and (iii) 4.8 Å between...
d-[1-13C]Ala and the [15N]amide at the C-terminus of LCTA-1421. Additional harmonic constraints (5 kcal/mol) were added to prevent the simulation from deviating from the NMR structure.

■ RESULTS

13C{15N}REDOR NMR of the PG–LCTA-1421 Complex. 13C{15N}REDOR spectra during 32.4 ms dipolar evolution for whole cells of S. aureus labeled with d-[1-13C]Ala and L-[3-13C]Ala complexed with LCTA-1421 are shown in Figure 3. For S. aureus grown in the presence of alaphosphin (5 μg/mL), the provisioned d-[1-13C]Ala does not scramble to L-[1-13C]Ala. The 13C carbonyl carbons of d-[1-13C]Ala are dephased at 175 ppm (red), and the 13C methyl carbon of L-[3-13C]Ala appears at 30 ppm (blue). The chemical shift assignments for the 13C carbonyl carbons of d-[1-13C]Ala-d-[1-13C]Ala were determined using a 13C→15N transferred-echo double-resonance NMR experiment with whole cells of S. aureus labeled with d-[1-13C]Ala and [15N]Gly.33 In the difference (ΔS) spectrum, both 175 and 30 ppm peaks are dephased by the 15N atoms of LCTA-1421. An expanded region centered around 175 ppm (right panel) shows that the 13C carbonyl carbon of d-[1-13C]Ala is partially resolved. The 178 ppm peak is assigned to the carboxyl carbonyl carbon and the 173 ppm peak to the peptidyl carbonyl carbon of the d-[1-13C]Ala-d-[1-13C]Ala segment in the PG stem.33 The 13C methyl carbons of L-[3-13C]Ala appear at 175 ppm (red), and the 13C methyl carbon of L-[3-13C]Ala appear at 178 ppm peak is assigned to the carboxyl carbonyl carbon and the 85 ppm peak is assigned to the peptidyl carbonyl carbon of D-[1-13C]Ala is shown as a red solid line, and the curve of the 13C methyl carbon of the bound D-[1-13C]Ala-D-[1-13C]Ala are dephased exclusively by the C-terminal [15N]amide of LCTA-1421 for investigating the interaction. Figure 4 shows the 13C{15N} REDOR NMR of the LCTA-1110 complex. The calculated 13C{15N} REDOR distance constraints for the PG–LCTA-1421 complex. The calculated 13C{15N} REDOR dephasing curves for whole cells of S. aureus labeled with d-[1-13C]Ala and L-[3-13C]Ala complexed with LCTA-1421 are shown in Figure 6 (left). The dephasing curve for the carboxyl d-[1-13C]Ala is shown as a red solid line, and the curve of the 13C methyl carbon of the bound d-[1-13C]Ala-D-[1-13C]Ala segment.

15N{19F} REDOR Distance Constraints for the PG–LCTA-1214 Complex. The calculated 13C{15N} REDOR dephasing curves for whole cells of S. aureus labeled with d-[1-13C]Ala and L-[3-13C]Ala complexed with LCTA-1421 are shown in Figure 6 (left). The dephasing curve for the carboxyl d-[1-13C]Ala is shown as a red solid line, and the curve of the methyl carbon of d-[1-13C]Ala-D-[1-13C]Ala is shown as a red dotted line. Each calculated dephasing curve includes the 13C natural abundance contribution, which is fully dephased to 1% by 2 ms. The calculated 13C–15N distances from the Asn [15N]amide of LCTA-1421 to the carboxyl and peptidyl carbonyl carbons of the bound d-[1-13C]Ala-D-[1-13C]Ala are 4.8 and 5.1 Å, respectively. The 13C–15N distance from the C-terminal [15N]amide of LCTA-1421 to the alanyl methyl carbon of L-[3-13C]Ala (30 ppm) is 3.5 Å. This positions the [15N]amide of the asparagine side chain in LCTA-1421 at 3.5 Å from the L-[3-13C]Ala and the C-terminal [15N]amide of LCTA-1421.
E. faecium vancomycin-resistant [1-13C]Ala5 dipeptide, respectively. Distances are illustrated in Figure 6 (bottom) and are determined by 15N{13C}REDOR are in reasonable agreement for the C-terminal [15N]amide dephasing (blue circles) for a 13C−15N distance of 4.3 and 5.5 Å. The blue line is the calculated dephasing curve for asparagine dephasing (red circles) for two 13C−15N distances of 4.3 and 5.5 Å. The red line is the calculated dephasing curve for asparagine [15N]amide dephasing in Figure 6 (right). The red line is the calculated dephasing curve for asparagine [15N]amide dephasing in the full-echo spectrum (S0) at the top. The amide regions of the full-echo and difference spectra are inset. The [15N]amide of Asn in LCTA-1421 found at 92 ppm is resolved from the [15N]amide of the C-terminal amide at 85 ppm. The spectra were the result of the accumulation of 248770 scans.

Figure 5. 15N{13C} REDOR spectra during the 16.2 ms dipolar evolution of whole cells of S. aureus grown in defined medium containing d-[1-13C]Ala and l-[3-13C]Ala complexed to LCTA-1421. The full-echo spectrum (S0) is shown at the bottom and the REDOR difference spectrum (ΔS) at the top. The amide regions of the full-echo and difference spectra are inset. The [15N]amide of Asn in LCTA-1421 found at 92 ppm is resolved from the [15N]amide of the C-terminal amide at 85 ppm. The spectra were the result of the accumulation of 248770 scans.

4.8 Å from the 13C atoms in the bound d-[1-13C]Ala and l-[1-13C]Ala dipeptide, respectively.

Comparable 13C−15N distances are determined from 15N-{13C}REDOR dephasing curves shown in Figure 6 (right). The red line is the calculated dephasing curve for asparagine [15N]amide in two 13C−15N distances of 4.3 and 5.5 Å. The red line is the calculated dephasing curve for the C-terminal [15N]amide of LCTA-1421 dephasing (blue circles) for a 13C−15N distance of 3.8 Å. The 13C−15N distances determined by 15N{13C}REDOR are in reasonable agreement with the 13C{15N}REDOR results. The measured 13C−15N distances are illustrated in Figure 6 (bottom) and are summarized in Supplementary Table S1. The measured REDOR distances are used as constraints for the molecular dynamics simulation of LCTA-1421 complexed to the PG stem structure shown in Figure 6.

Antimicrobial Activities of the Carboxyl-Terminally Modified Glycopeptide Antibiotics. Supplementary Table S2 shows the minimal inhibitory concentrations (MICs) of vancomycin, eremomycin, LCTA-1421, and LCTA-1110 against vancomycin-susceptible and -resistant strains of Gram-positive bacteria. The C-terminally modified glycopeptides, LCTA-1421 and LCTA-1110, exhibit mild improved activities across the board against vancomycin-susceptible Gram-positive bacteria, vancomycin intermediate-resistant S. aureus, and vancomycin-resistant E. faecium and E. faecalis.

Street Notes

Antimicrobial Activities of the Carboxyl-Terminally Modified Glycopeptide Antibiotics. Supplementary Table S2 shows the minimal inhibitory concentrations (MICs) of vancomycin, eremomycin, LCTA-1421, and LCTA-1110 against vancomycin-susceptible and -resistant strains of Gram-positive bacteria. The C-terminally modified glycopeptides, LCTA-1421 and LCTA-1110, exhibit mild improved activities across the board against vancomycin-susceptible Gram-positive bacteria, vancomycin intermediate-resistant S. aureus, and vancomycin-resistant E. faecium and E. faecalis.

Discussion

The LCTA-1421 Asparagine Side Chain Functions as a “Flap”. Structure–activity studies have shown that the asparagine is essential for the activities in Type I glycopeptides.2,11,22 Schäfer et al.34 proposed that the vancomycin asparagine side chain functions as a gate to regulate access of the ligand to the binding cleft. In an “open” conformation in the X-ray crystal structure of an asymmetric vancomycin dimer, the asparagine side chain swings out of the binding cleft with an acetate ion occupying the d-Ala-d-Ala binding site. In a “closed” conformation, the asparagine side chain swings into the binding cleft.10 An X-ray crystal structure of vancomycin bound to diacetyl-l-Lys-d-Ala-d-Ala (Figure 2, left) also showed that the asparagine side chain swings out of the binding cleft to accommodate ligand binding. Loll et al.35 proposed that the asparagine side chain functions as a “flap” in the absence of a ligand, acting as a ligand surrogate by occupying the binding site. The “flap” prevents the hydration of the ligand binding cavity, which is energetically favorable as the water molecules placed within a highly polarized binding pocket are thought to be difficult to remove for the ligand to bind.

It is unclear how critical the “flap” is for the glycopeptide activity. As shown in Supplementary Figure S1, Type III and IV glycopeptides have aromatic residues at amino acid positions 1 and 3 that are cross-linked by a phenolic—ether linkage. This rigid macrocyclic ring structure is incompatible with the proposed “flap” function in vancomycin, and furthermore, glycopeptide antibiotics of Types III and IV exhibit potent antimicrobial activities, even in the absence of the “flap”, suggesting that asparagine’s “flap” mechanism might not have a significant effect.

The LCTA-1421 Asparagine Side Chain Forms a Binding Cleft. REDOR measurements position the asparagine [15N]amide of LCTA-1421 5.1 and 4.8 Å from the 13C carbonyl carbons of d-[1-13C]Ala-d-[1-13C]Ala, respectively, of the bound PG stem (Figure 6). The proximity of the asparagine [15N]amide to the binding cleft is contrary to the average N−C distances of 7.9 and 6.1 Å determined by X-ray diffraction on vancomycin’s hexamer repeat unit (PDB entry 1FVM). Each individual N−C distance in vancomycin’s hexamer unit is tabulated and shown in Supplementary Table S3. In an X-ray crystal structure, the asparagine side chain of vancomycin is positioned out of the d-Ala-d-Ala binding site; in contrast, solid-state NMR positions the asparagine side chain closer to the d-Ala-d-Ala binding pocket. We believe that the crystallization of vancomycin, forming a hexamer repeat unit, affects the conformation of the vancomycin−dipeptide structure. In comparison, solution-state NMR of the chloroeremomycin dimer determines that the corresponding N−C distances are 6.9 and 4.4 Å.10 The solution-state NMR measurement agrees closely with REDOR NMR distance measurements of 5.1 and 4.8 Å (Figure 6). However, one caveat is that the solution NMR structure represents a chloroeremomycin bound to a model peptide mimicking PG as a dimer. We have found that glycopeptide antibiotics that readily form a dimer in solution6−38 when complexed to whole cells of S. aureus are found as a monomer when bound to PG.15,16,39 Even one of the strongest dimer-forming glycopeptides, oritavancin, is found as a monomer when complexed to the PG in whole cells of S. aureus.16 Hence, distance constraints determined by REDOR NMR represent the in vivo glycopeptide conformation of monomeric PG binding in the cell wall of intact whole cells, without any effects from drug dimerization, PG mimic binding, or crystal lattice constraints.

We propose an alternative relationship between the asparagine side chain and the formation of the ligand binding site. The asparagine side chain does not directly form a
hydrogen bond with D-Ala-D-Ala, but its proximity to the bound dipeptide strongly suggests a possible interaction with the N-methylleucine (first amino acid of LCTA-1421). The interaction of the asparagine side chain with the N-methylleucine can form a binding cavity that can stabilize dipeptide binding. Either Edman degradation of the N-methylleucine in eremomycin (the parent compound of LCTA-1421) or the replacement of asparagine with glutamine or aspartate can disrupt this action, thus decreasing antimicrobial activities. In the case of substitution of asparagine with isoaspartate, the D-Ala-D-Ala binding site is destroyed by rearrangement, forming CDP-I, which is devoid of antimicrobial activities. REDOR distance constraints indicate that the asparagine and leucine side chains constitute a part of a hydrophobic pocket necessary for D-Ala-D-Ala binding. The proposed interaction between the asparagine and N-methylleucine in the presence of dipeptide will require further investigation.

The Carboxyl Terminus of LCTA-1421 Interacts with the Non-D-Ala-D-Ala Segments of PG. The solid-state NMR measurements position the L-Ala segment of the bound PG stem near the C-terminus of LCTA-1421 (Figure 6). The measured $^{13}$C-$^{15}$N distance between the C-terminal $^{15}$N-amide of LCTA-1421 and the L-[3-$^{13}$C]Ala of the PG stem is 3.5 Å as determined by $^{13}$C($^{15}$N) REDOR (Figure 3) and 3.8 Å as determined by $^{15}$N($^{13}$C) REDOR (Figure 5). The results are in excellent agreement with the position of fluorine in LCTA-1110 bound to PG in intact whole cells of S. aureus determined at 6.0 Å from the $^{15}$N of L-[1-$^{15}$N]Ala of the bound PG stem. These structural measurements are consistent with the C-terminus of glycopeptide interacting with the non-D-Ala-D-Ala segments of PG.

The MIC measurements (Supplementary Table S2) show that the C-terminal modifications enhance the antimicrobial activities of glycopeptides. The MIC values of LCTA-1421 and LCTA-1110 are greater than those of the parent compound eremomycin. The activities are enhanced because the C-terminal modification enhances glycopeptide−PG binding through interactions that involve more than just D-Ala-D-Ala binding. REDOR distance constraints position the C-terminus of LCTA-1421 in the vicinity of the L-Ala of the bound PG stem structure in intact whole cells of S. aureus. This non-D-Ala-D-Ala interaction is critical for permitting the binding of the drug to the D-Ala-D-Lac-terminated PG stem found in vancomycin-resistant enterococci and thus is likely to be responsible for the small enhancement in the activity of LCTA-1421 against vancomycin-resistant and intermediate-resistant pathogens (Supplementary Table S2).

In conclusion, glycopeptide antibiotics exhibit potent antibacterial activities by inhibiting PG biosynthesis in Gram-
positive bacteria. The primary glycopeptide–PG interaction involves the aglycon structure of the glycopeptide binding to the D-Ala-D-Ala of the PG stem structure. However, structure–activity relationship studies of chemically modified glycopeptides suggest that drug–target interaction is complex. In the case of C-terminally modified glycopeptides, the antibiotic C-terminal interactions with the non-D-Ala-D-Ala segments of PG improve drug activity. To investigate interactions of glycopeptides with non-D-Ala-D-Ala segments of PG, we complexed LCTA-1421 to intact whole cells of *S. aureus* and characterized the PG–LCTA-1421 complex using solid-state NMR. We have synthesized LCTA-1421 for this study with selective incorporations of the 15N isotope into its aglycon structure, one at the L-[1-13C]Ala segment of the bound PG stem and characterized the [15N]amide-carboxyremomycin; LCTA-1110, eremomycin p-fluorophenylpirerazinamide; [15N][13C], nitrogen channel observation with carbon dephasing; PG, peptidoglycan; CPMAS, cross-polarization at magic-angle spinning; lipid II, N-acetylgalactosamine-N-acetyl-muramyl-pentapeptide-pyrophosphate-undecaprenol; REDOR, rotational-echo double resonance; PyBOP, (benzotriazol-1-yl oxy)trypiyrrolidinophosphonium hexafluorophosphate; PDB, Protein Data Bank.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.biochem.6b00188.

Chemical structures of classes of glycopeptide antibiotics, a summary table of 13C–15N REDOR distance constraints determined for LCTA-1421 bound to peptidoglycan in intact whole cells of *S. aureus*, and minimal inhibitory concentrations of C-terminally modified glycopeptide antibiotics against vancomycin-resistant and -susceptible pathogens (PDF)

## AUTHOR INFORMATION

### Corresponding Author

*E-mail: Sung_J_Kim@baylor.edu.

### Funding

This paper is based on work supported by National Institutes of Health Grant GM116130.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

The authors acknowledge Southern Methodist University’s Center for Scientific Computation for computing resources and thank Ms. Svetlana E. Solovieva and Ms. Elena P. Mirchink, D.Sc. (Gause Institute of New Antibiotics), for the antibacterial activity of LCTA compounds.

## REFERENCES


